Planet Briefing

First published 10/3/2026, 10:04:15 PM · Last updated 10/3/2026, 10:04:15 PM

Matching-Adjusted Indirect Comparison of Oral Paclitaxel (Liporaxel) Versus Weekly Intravenous Paclitaxel in Advanced Gastric Cancer

A journal article reports a matching-adjusted indirect comparison evaluating an oral paclitaxel formulation (Liporaxel) against weekly intravenous paclitaxel for advanced gastric cancer. Publisher: XMLink; published 2026-01-01.

Hair matting, change in hair shaft structure after few sessions of chemotherapy — Illustrative image: Hair matting, change in hair shaft structure after few sessions of chemotherapy — NewAgeAesthetics/Wikimedia Commons, CC BY-SA 4.0

Categories: public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 4/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 5/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 1/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The comparison is relevant to clinical and research evaluation of treatment options for advanced gastric cancer.

Sources

Matching-Adjusted Indirect Comparison of Oral Paclitaxel (Liporaxel <sup>®</sup> ) Versus Weekly Intravenous Paclitaxel in Advanced Gastric CancerMetadata provided by Crossref. Usage terms

Report an issue